RT Journal Article
T1 Spanish Lung Cancer Group SCAT trial: surgical audit to lymph node assessment based on IASLC recommendations
A1 Jarabo Sarceda, Jose Ramon
A1 Bolufer Nadal, Sergio
A1 Mongil Poce, Roberto
A1 Lopez de Castro, Pedro
A1 Moreno Balsalobre, Ramon
A1 Penalver Cuesta, Juan Carlos
A1 Embun Flor, Raul
A1 Pac Ferrer, Joaquin
A1 Algar Algar, Francisco Javier
A1 Gamez Garcia, Antonio Pablo
A1 Jimenez, Marcelo F.
A1 Gabriel Sales-Badia, Jesus
A1 Pereira, Eva
A1 Massuti, Bartomeu
A1 Provencio, Mariano
A1 Hernando Trancho, Florentino
K1 Non-small cell lung cancer (NSCLC)
K1 surgery
K1 lymph node dissection (LND)
K1 survival
K1 International association
K1 Prognostic value
K1 Stage-i
K1 Resection
K1 Survival
K1 Number
K1 Pattern
K1 Quality
K1 Impact
K1 Ratio
AB Background: The Spanish Customized Adjuvant Therapy (SCAT) trial assessed the role of individualized adjuvant therapy in clinical N0 incidental pN1 and/or N2 non-small cell lung cancer (NSCLC) completely resected. We assessed surgical topics with an in-depth analysis of quality of lymphadenectomy based on International Association for the Study of Lung Cancer (IASLC) recommendations.Methods: Patients with information about lymphadenectomy available were included (N=451). Prospectively collected data about tumor, type of resection, and postoperative morbidity and quality of lymph node dissection (LND) were retrospectively evaluated. Role of lymph node assessment on survival was analyzed using Kaplan-Meier curves, using regression models to identify prognostic factors.Results: In 33.7%, 17.7% and 49.9% of cases, regions 7, 10 and 11 respectively were not assessed. In 21.1% of patients, less than three lymph node regions were biopsied, while in 19.6% of patients less than six lymph nodes were assessed. In 53,4% of patients only one N1 region was evaluated. From patients with positive N2, 8.9% had no N1 regions biopsied. Twenty-nine percent of patients with at least one N2 lymph node resected shown the highest region involved. Thirty-day postoperative mortality was unknown. Five-year overall survival (OS) was 61.7% (95% CI: 55.4-67.4%), 51.5% (95% CI: 39.2-62.4%) and 42.3% (95% CI: 32.1-52.2%) for patients with N1, N2 and N1+N2 disease, respectively (P
PB Ame publ co
SN 2218-6751
YR 2021
FD 2021-04-01
LK http://hdl.handle.net/10668/19478
UL http://hdl.handle.net/10668/19478
LA en
DS RISalud
RD Apr 7, 2025